We were able to confirm that AURKis could induce IFN in vivo, and that tumor growth inhibition by alisertib depended on immune system involvement, consistent with the hypothesis that AURKi-mediated IFN induction and ERV expression created a more favorable environment for immune recognition. Here, IFNA1 is linked to neoplasm.